1. Show article details.

    Hologic to Webcast Presentations at Upcoming Investor Conferences

    Business Wire – 5:02 PM ET 02/18/2020

    Hologic, Inc. (HOLX) announced today that the Company will present at these upcoming investor conferences: Each presentation will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investors.hologic.com. The webcasts will be available for 30 days following the events.

  2. Show article details.

    Hologic Launches New Scalable Options for Panther System in the United States and Europe

    Business Wire – 8:08 AM ET 02/05/2020

    New products offer increased flexibility and efficiency for low- to high-volume molecular testing laboratories New product offerings within the Panther Scalable Solutions portfolio are now commercially available in the United States and Europe, Hologic (HOLX) announced today. This press release features multimedia.

  3. Show article details.

    Medical Devices Are Key to Solving the Healthcare Industry's Persistent Problems

    PR Newswire – 9:00 AM ET 02/04/2020

    NEW YORK, Feb. 4, 2020 While the healthcare industry has made great strides in the last several years, many complex issues within the industry remain unsolved. The Food and Drug Administration also recognizes the innovative progress the medical device market has started to go through.

  4. Show article details.

    BRIEF-Hologic Q1 Non-Gaap Earnings Per Share $0.61

    Reuters – 5:24 PM ET 01/29/2020

    Hologic Inc (HOLX): * HOLOGIC ANNOUNCES FINANCIAL RESULTS FOR FIRST QUARTER OF FISCAL 2020. * Q1 NON-GAAP EARNINGS PER SHARE $0.61. * Q1 GAAP EARNINGS PER SHARE $1.43. * Q1 EARNINGS PER SHARE ESTIMATE $0.61 -- REFINITIV IBES DATA. * Q1 REVENUE $850.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $839.8 MILLION. * BOARD AUTHORIZED AN ADDITIONAL $500 MILLION SHARE REPURCHASE AUTHORIZATION TO BEGIN IN Q3.

  5. Show article details.

    Hologic Announces Financial Results for First Quarter of Fiscal 2020

    Business Wire – 4:02 PM ET 01/29/2020

    – Revenue of $850.5 Million Grows 2.4%, 2.8% in Constant Currency –. – Excluding Acquisitions and Divestitures, Revenue Increases 4.1%, 4.6% in Constant Currency –. – Company Posts GAAP Diluted EPS of $1.43 Due to One-Time Tax Benefit, Non-GAAP Diluted EPS of $0.61 –. – Following Cynosure Divestiture, Company Expects Faster Revenue Growth, Higher EPS –. MARLBOROUGH, Mass.

  6. Show article details.

    SuperSonic Imagine Announces a Change in Governance

    Business Wire – 12:00 PM ET 01/23/2020

    Regulatory News: SuperSonic Imagine, a company specialising in medical ultrasound imaging, today announced a change in governance with the departure of General Manager Michele Lesieur, effective immediately. With this change, Antoine Bara, currently a member of the Company’s Board of Directors, has been appointed General Manager.

  7. Show article details.

    BRIEF-Hologic Inc Says CEO Stephen P. Macmillan's 2019 Total Compensation Was $12.37 Million

    Reuters – 4:42 PM ET 01/22/2020

    Hologic Inc (HOLX): * Hologic Inc (HOLX) - CEO STEPHEN P. MACMILLAN'S 2019 TOTAL COMPENSATION WAS $12.37 MILLION VERSUS $42.04 MILLION IN 2018 - SEC FILING. * Hologic Inc (HOLX) - CEO STEPHEN P. MACMILLAN'S 2018 TOTAL COMPENSATION INCLUDED $27.18 MILLION IN STOCK AWARDS Source Further company coverage:

  8. Show article details.

    Hologic’s First Sustainability Report Highlights Global Corporate Citizenship Efforts in Fiscal 2019

    Business Wire – 4:05 PM ET 01/22/2020

    Hologic, Inc. (HOLX) announced today the release of the Company’s first sustainability report, Making a Unique Difference in the World. In the report, the Company highlights its global corporate citizenship efforts around the key environmental, social and governance areas that are important to the company’s investors, employees, customers and other stakeholders.

  9. Show article details.

    BRIEF-Hologic Announces Preliminary Financial Results For First Quarter Of Fiscal 2020

    Reuters – 6:06 PM ET 01/12/2020

    Hologic Inc (HOLX): * HOLOGIC ANNOUNCES PRELIMINARY FINANCIAL RESULTS FOR FIRST QUARTER OF FISCAL 2020. * Q1 REVENUE $850.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $839.3 MILLION. * BOARD OF DIRECTORS APPROVES NEW $500 MILLION SHARE REPURCHASE PLAN Source text for Eikon: Further company coverage:

  10. Show article details.

    Hologic Announces Preliminary Financial Results for First Quarter of Fiscal 2020

    Business Wire – 5:00 PM ET 01/12/2020

    -- Revenue of $850.5 Million Grows 2.4%, 2.8% in Constant Currency -- -- Excluding Acquisitions and Divestitures, Revenue Increases 4.1%, 4.6% in Constant Currency -- -- Board of Directors Approves New $500 Million Share Repurchase Plan -- MARLBOROUGH, Mass.

  11. Show article details.

    Hologic to Announce Financial Results for the First Quarter of Fiscal 2020 on Wednesday, January 29, 2020

    Business Wire – 8:22 AM ET 01/07/2020

    Hologic, Inc. (HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2020 on Wednesday, January 29, after the market closes. Interested participants may listen to the call by dialing 800-458-4121 or +1 323-794-2093 and referencing access code 7777146.

  12. Show article details.

    Hologic to Webcast Presentation at the 38th Annual J.P. Morgan Healthcare Conference

    Business Wire – 8:30 AM ET 12/31/2019

    Hologic, Inc. (HOLX) announced today that the Company will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13 at 8 a.m. Pacific Time.

  13. Show article details.

    Hologic Completes Divestiture of Cynosure Medical Aesthetics Business

    Business Wire – 9:24 AM ET 12/30/2019

    Hologic, Inc. (HOLX) announced today that it has completed the previously announced divestiture of its Cynosure medical aesthetics business to an affiliate of investment funds managed by Clayton, Dubilier & Rice for a total purchase price of $205 million in cash, less certain closing adjustments.

  14. Hologic stock price target raise to $52 vs. $48 at Stifel

    MarketWatch – 7:59 AM ET 12/13/2019
  15. Show article details.

    Women’s Healthcare Leader Hologic to Showcase Comprehensive Portfolio of Breast and Skeletal Health Solutions at RSNA 2019

    Business Wire – 7:00 AM ET 12/02/2019

    --Company reinforces breast health leadership with innovative new products, breakthrough Artificial Intelligence-powered platform and prestigious IMV ranking-- Hologic, Inc. (HOLX) will showcase its comprehensive portfolio of breast and skeletal health products, including screening, interventional, surgical, ultrasound and skeletal solutions, in Booth #2511 at the 105th Scientific Assembly and Annual...

  16. Show article details.

    SuperSonic Imagine Unveils Its Latest Innovations at the French Days of Radiology (JFR) 

    GlobeNewswire – 12:00 PM ET 10/08/2019

    AIX-EN-PROVENCE, France, Oct. 08, 2019 -- SuperSonic Imagine, a company specialising in medical ultrasound imaging, is expanding its product range and will for the first time present a suite of new ultrasound markers1 alongside its new ultrasound platform, Aixplorer MACH® 20, at the JFR congress.

Page:

Today's and Upcoming Events

  • Apr
    29

    HOLX to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • Jan
    29

    HOLX announced Q1 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.